葛兰素史克授权Halozymer的Enhenze药物输送技术

2026-05-08 01:01

Halozyme Therapeutics (HALO) announced on Thursday that GSK (GSK) has reached an agreement to license its Enhanze drug delivery technology to advance subcutaneously delivered cancer drugs.
The companies will initiate their first clinical trial this year as they seek the development and commercialization of injectable versions of multiple cancer drugs, including antibody-drug conjugates, under the global collaboration and license agreement.
Per the terms, Halozyme (HALO) will additionally issue an option that allows the British drugmaker to develop Enhanze-based therapies targeting other drug targets in the future.
In exchange, the company will receive an undisclosed upfront payment from GSK in addition to royalties on net sales of products based on Enhanze, according to a press release from the company. Specific financial terms of the transaction were not disclosed.

More on GSK, Halozyme Therapeutics